Viking Therapeutics (1VT) Stock Forecast & Price Target

Compare

69 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1VT Analyst Ratings

Strong Buy

16 Buy

2 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Viking

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1VT Stock 12 Month Forecast

Average Price Target

€76.80

▲(259.57% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is €76.80 with a high forecast of €106.81 and a low forecast of €24.78. The average price target represents a 259.57% change from the last price of €21.36.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"€21","64":"€64","107":"€107","42.5":"€42.5","85.5":"€85.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":106.8144175,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€106.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":76.8038387592,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€76.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.78094486,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€24.78</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,42.5,64,85.5,107],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.495,29.904185961538463,36.31337192307692,42.722557884615384,49.131743846153846,55.54092980769231,61.95011576923076,68.35930173076923,74.76848769230769,81.17767365384616,87.58685961538461,93.99604557692308,100.40523153846154,{"y":106.8144175,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.495,27.595679904553847,31.696359809107694,35.79703971366154,39.89771961821539,43.99839952276923,48.099079427323076,52.199759331876926,56.300439236430776,60.40111914098462,64.50179904553846,68.60247895009232,72.70315885464616,{"y":76.8038387592,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.495,23.593918835384617,23.692837670769233,23.79175650615385,23.89067534153846,23.989594176923077,24.088513012307693,24.18743184769231,24.286350683076925,24.38526951846154,24.484188353846154,24.58310718923077,24.682026024615386,{"y":24.78094486,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":57.44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.34,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.56,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.24,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.03,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.005,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.495,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€106.81

Average Price Target€76.80

Lowest Price Target€24.78

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Justin Zelin

BTIG

€107.13

Buy

401.54%

Upside

Reiterated

09/22/25

Viking Therapeutics: Strong Buy Rating Amid Strategic Positioning and Acquisition Potential in the Metabolic Disease MarketWe see today's announced acquisition following Roche's (RHHBY , Not Rated) recent acquisition of 89bio (ETNB, Carmot (RHHBY) for a total value of up to $3.5B and $3.1B respectively as representative of large pharma's strong interest in the obesity and metabolic disease platforms and willingness to pay a premium for acquisitions, providing positive readthroughs to Viking. We view Viking as having one of the few remaining late-stage and class-leading obesity franchises with both oral and subcutaneous programs, with increasing strategic premium given scarcity valuation. We expect this transaction will sharpen Viking's clinical updates and strategic optionality, bolstering sentiment ahead of key clinical readouts.

Biren Amin

Piper Sandler

€60.85

Buy

184.87%

Upside

Reiterated

09/08/25

Viking Therapeutics (VKTX) Gets a Buy from Piper Sandler

David Lebowitz

Citi

€32.57→€24.85

Hold

16.36%

Upside

Reiterated

08/20/25

Viking Therapeutics (VKTX) Gets a Hold from Citi

Michael Ulz

Morgan Stanley

€83.99

Buy

293.21%

Upside

Reiterated

08/20/25

Morgan Stanley Keeps Their Buy Rating on Viking Therapeutics (VKTX)

Yale Jen

Laidlaw

€94.27

Buy

341.35%

Upside

Reiterated

08/20/25

Laidlaw Keeps Their Buy Rating on Viking Therapeutics (VKTX)Laidlaw analyst Yale Jen reiterated a Buy rating and $110.00 price target on Viking Therapeutic (NASDAQ: VKTX).

Thomas Smith

Leerink Partners

€101.13

Buy

373.45%

Upside

Reiterated

08/19/25

Viking Therapeutics weakness 'overdone,' says LeerinkViking Therapeutics weakness 'overdone,' says Leerink

Joon Lee

Truist Financial

€64.28

Buy

200.92%

Upside

Reiterated

08/19/25

Truist Financial Sticks to Its Buy Rating for Viking Therapeutics (VKTX)

Annabel Samimy

Stifel Nicolaus

€81.42

Buy

281.17%

Upside

Reiterated

08/19/25

Viking Therapeutics' VK2735: Promising Phase 2 Results Highlight Strong Market Potential and Commercial Viability

Ryan Deschner

Raymond James

€104.56

Buy

389.50%

Upside

Reiterated

08/19/25

Raymond James Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)

Andy Hsieh

William Blair

―

Buy

―

Reiterated

08/19/25

Viking Therapeutics: Buy Rating Affirmed Amid Promising VK2735 Trial Results and Market Overreaction

Hardik Parikh

J.P. Morgan

―

Buy

―

Reiterated

08/19/25

JPMorgan says Viking weight loss drug still offers strong efficacy JPMorgan says Viking weight loss drug still offers strong efficacy

Joseph Pantginis

H.C. Wainwright

€87.42

Buy

309.26%

Upside

Reiterated

08/19/25

Positive Buy Rating for Viking Therapeutics Driven by Promising VK2735 Trial Results and Market Potential

Roger Song

Jefferies

€86.56

Buy

305.24%

Upside

Reiterated

08/19/25

Market 'overreacting' to Viking Therapeutics adverse events, says JefferiesMarket 'overreacting' to Viking Therapeutics adverse events, says Jefferies

Naz Rahman

Maxim Group

€59.99

Buy

180.86%

Upside

Reiterated

08/19/25

Viking Therapeutics (VKTX) Gets a Buy from Maxim Group

Jay Olson

Oppenheimer

€85.7

Buy

301.23%

Upside

Reiterated

08/18/25

Oppenheimer Sticks to Their Buy Rating for Viking Therapeutics (VKTX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Justin Zelin

BTIG

€107.13

Buy

401.54%

Upside

Reiterated

09/22/25

Biren Amin

Piper Sandler

€60.85

Buy

184.87%

Upside

Reiterated

09/08/25

Viking Therapeutics (VKTX) Gets a Buy from Piper Sandler

David Lebowitz

Citi

€32.57→€24.85

Hold

16.36%

Upside

Reiterated

08/20/25

Viking Therapeutics (VKTX) Gets a Hold from Citi

Michael Ulz

Morgan Stanley

€83.99

Buy

293.21%

Upside

Reiterated

08/20/25

Morgan Stanley Keeps Their Buy Rating on Viking Therapeutics (VKTX)

Yale Jen

Laidlaw

€94.27

Buy

341.35%

Upside

Reiterated

08/20/25

Laidlaw Keeps Their Buy Rating on Viking Therapeutics (VKTX)Laidlaw analyst Yale Jen reiterated a Buy rating and $110.00 price target on Viking Therapeutic (NASDAQ: VKTX).

Thomas Smith

Leerink Partners

€101.13

Buy

373.45%

Upside

Reiterated

08/19/25

Viking Therapeutics weakness 'overdone,' says LeerinkViking Therapeutics weakness 'overdone,' says Leerink

Joon Lee

Truist Financial

€64.28

Buy

200.92%

Upside

Reiterated

08/19/25

Truist Financial Sticks to Its Buy Rating for Viking Therapeutics (VKTX)

Annabel Samimy

Stifel Nicolaus

€81.42

Buy

281.17%

Upside

Reiterated

08/19/25

Viking Therapeutics' VK2735: Promising Phase 2 Results Highlight Strong Market Potential and Commercial Viability

Ryan Deschner

Raymond James

€104.56

Buy

389.50%

Upside

Reiterated

08/19/25

Raymond James Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)

Andy Hsieh

William Blair

―

Buy

―

Reiterated

08/19/25

Viking Therapeutics: Buy Rating Affirmed Amid Promising VK2735 Trial Results and Market Overreaction

Hardik Parikh

J.P. Morgan

―

Buy

―

Reiterated

08/19/25

JPMorgan says Viking weight loss drug still offers strong efficacy JPMorgan says Viking weight loss drug still offers strong efficacy

Joseph Pantginis

H.C. Wainwright

€87.42

Buy

309.26%

Upside

Reiterated

08/19/25

Positive Buy Rating for Viking Therapeutics Driven by Promising VK2735 Trial Results and Market Potential

Roger Song

Jefferies

€86.56

Buy

305.24%

Upside

Reiterated

08/19/25

Market 'overreacting' to Viking Therapeutics adverse events, says JefferiesMarket 'overreacting' to Viking Therapeutics adverse events, says Jefferies

Naz Rahman

Maxim Group

€59.99

Buy

180.86%

Upside

Reiterated

08/19/25

Viking Therapeutics (VKTX) Gets a Buy from Maxim Group

Jay Olson

Oppenheimer

€85.7

Buy

301.23%

Upside

Reiterated

08/18/25

Oppenheimer Sticks to Their Buy Rating for Viking Therapeutics (VKTX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Viking Therapeutics

1 Month

xxx

Success Rate

13/21 ratings generated profit

Average Return

+12.93%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.90% of your transactions generating a profit, with an average return of +12.93% per trade.

3 Months

xxx

Success Rate

12/22 ratings generated profit

Average Return

+18.84%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +18.84% per trade.

1 Year

Naz RahmanMaxim Group

Success Rate

13/22 ratings generated profit

Average Return

+142.49%

reiterated a buy rating last month

Copying Naz Rahman's trades and holding each position for 1 Year would result in 59.09% of your transactions generating a profit, with an average return of +142.49% per trade.

2 Years

xxx

Success Rate

13/22 ratings generated profit

Average Return

+210.08%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 59.09% of your transactions generating a profit, with an average return of +210.08% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1VT Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1VT has received 32 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 1VT average Analyst price target in the past 3 months is 76.80.

Each month's total comprises the sum of three months' worth of ratings.

1VT Financial Forecast

1VT Earnings Forecast

Next quarter’s earnings estimate for 1VT is -€0.60 with a range of -€0.70 to -€0.43. The previous quarter’s EPS was -€0.50. 1VT beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 1VT has Preformed in-line its overall industry.

No data currently available

1VT Sales Forecast

Next quarter’s sales forecast for 1VT is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 1VT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 1VT has Preformed in-line its overall industry.

1VT Stock Forecast FAQ

What is DE:1VT’s average 12-month price target, according to analysts?

Based on analyst ratings, Viking Therapeutics’s 12-month average price target is 76.80.

What is DE:1VT’s upside potential, based on the analysts’ average price target?

Viking Therapeutics has 259.57% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Viking Therapeutics a Buy, Sell or Hold?

Viking Therapeutics has a consensus rating of Strong Buy, which is based on 16 buy ratings, 2 hold ratings and 0 sell ratings.

What is Viking Therapeutics’s share price target?

The average share price target for Viking Therapeutics is 76.80. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €106.81 ,and the lowest forecast is €24.78. The average share price target represents 259.57% Increase from the current price of €21.36.

What do analysts say about Viking Therapeutics?

Viking Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of Viking Therapeutics?

To buy shares of DE:1VT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Viking Therapeutics (1VT) Stock Forecast & Price Target

1VT Analyst Ratings

1VT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Viking Therapeutics

1VT Analyst Recommendation Trends

1VT Financial Forecast

1VT Earnings Forecast

1VT Sales Forecast

1VT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts